Comparison between Asston Pharmaceuticals IPO and Kamsons Polymers IPO.
Asston Pharmaceuticals IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Kamsons Polymers IPO is a SME Bookbuilding proposed to list at NSE SME.
| Asston Pharmaceuticals IPO | Kamsons Polymers IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Sobhagya Capital Options Pvt.Ltd. | Hem Securities Ltd. |
| Registrar | Maashitla Securities Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | JSK Securities & Services Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Asston Pharmaceuticals IPO is up to ₹26.17 Cr whereas the issue size of the Kamsons Polymers IPO is up to ₹0.00 Cr. The final issue price of Asston Pharmaceuticals IPO is ₹123.00 per share and of Kamsons Polymers IPO is .
| Asston Pharmaceuticals IPO | Kamsons Polymers IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹115.00 per share | |
| Issue Price (Upper) | ₹123.00 per share | |
| Issue Price (Final) | ₹123.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | |
| Fresh Issue Size | 21,28,000 shares | 49,56,000 shares |
| Fresh Issue Size (Amount) | up to ₹26.17 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 12,36,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 21,28,000 shares | 61,92,000 shares |
| Issue Size Total (Amount) | up to ₹26.17 Cr | up to ₹0.00 Cr |
Asston Pharmaceuticals IPO opens on Jul 09, 2025, while Kamsons Polymers IPO opens on . The closing date of Asston Pharmaceuticals IPO and Kamsons Polymers IPO is Jul 11, 2025, and , respectively.
| Asston Pharmaceuticals IPO | Kamsons Polymers IPO | |
|---|---|---|
| Anchor Bid Date | Jul 08, 2025 | |
| Issue Open | Jul 09, 2025 | |
| Issue Close | Jul 11, 2025 | |
| Basis Of Allotment (Tentative) | Jul 14, 2025 | |
| Initiation of Refunds (Tentative) | Jul 15, 2025 | |
| Credit of Share (Tentative) | Jul 15, 2025 | |
| Listing date (Tentative) | Jul 16, 2025 | |
| Anchor Lockin End date 1 | Aug 13, 2025 | |
| Anchor Lockin End date 2 | Oct 12, 2025 |
Asston Pharmaceuticals IPO P/E ratio is 17.83, as compared to Kamsons Polymers IPO P/E ratio of .
| Asston Pharmaceuticals IPO | Kamsons Polymers IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Asston Pharmaceuticals Ltd.'s revenue increased by 62% and profit after tax (PAT) rose by 218% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 68.76 | 99.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 50.66 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 17.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹104.70 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.56% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 51.25% | 35.64% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.68 | 0.11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 40.36% | 28.49% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Asston Pharmaceuticals IPO Retail Individual Investors (RII) are offered 7,46,000 shares while in Kamsons Polymers IPO retail investors are offered 7,46,000 shares. Qualified Institutional Buyers (QIB) are offered 4,25,000 shares in Asston Pharmaceuticals IPO and in Kamsons Polymers IPO.
| Asston Pharmaceuticals IPO | Kamsons Polymers IPO | |
|---|---|---|
| Anchor Investor Reservation | 6,35,000 shares | |
| Market Maker Reservation | 1,13,000 shares | |
| QIB | 4,25,000 shares | |
| NII | 3,22,000 shares | |
| RII | 7,46,000 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 21,28,000 shares |
Asston Pharmaceuticals IPO subscribed 186.55x in total, whereas Kamsons Polymers IPO subscribed .
| Asston Pharmaceuticals IPO | Kamsons Polymers IPO | |
|---|---|---|
| QIB (times) | 85.76x | |
| NII (times) | 353.14x | |
| Big NII (times) | 424.47x | |
| Small NII (times) | 210.85x | |
| RII (times) | 172.06x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 186.55x |
